Clinical Trials Browser

Histiocytosis, Langerhans-Cell, Xanthogranuloma, Juvenile, Histiocytosis, Sinus, Histiocytic Disorders, Malignant, Erdheim-Chester Disease, Histiocytic Sarcoma

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2 Completed

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT02902029 2025-04-09

ImmunoCobiVem

Phase 2 Completed

186 enrolled

Dermatologic

Melanoma

NCT04722575 2025-03-13

NEO-TIM

Phase 2 Active not recruiting

95 enrolled

Dermatologic

Melanoma

NCT03224767 2025-02-18

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Phase 2 Active not recruiting

24 enrolled

CNS

Craniopharyngioma

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

Phase 2 Not yet recruiting

25 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

72 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04185831 2024-08-22

MEGALiT

Phase 2 Active not recruiting

167 enrolled

Other solid neoplasm

Solid Tumor

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

250 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT03395899 2024-06-18

ECLIPSE

Phase 2 Completed

71 enrolled

Breast

Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03430947 2023-09-14

RadioCoBRIM

Phase 2 Terminated

20 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03363867 2023-08-07

BEACON

Phase 2 Unknown

30 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02414750 2022-11-30

REPOSIT

Phase 2 Terminated

78 enrolled

Dermatologic

Melanoma

NCT02036086 2022-10-27

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Phase 2 Unknown

24 enrolled

Dermatologic

Melanoma

NCT03224208 2021-04-26

VECODUE

Phase 2 Terminated

9 enrolled

Dermatologic

Melanoma

NCT02303951 2021-02-03

NEO-VC

Phase 2 Terminated

47 enrolled

Dermatologic

Melanoma

NCT02968303 2020-06-05

COWBOY

Phase 2 Unknown

200 enrolled

Sarcoma

Sarcoma, Clear Cell

NCT02537600 2020-01-27

CONVERCE

Phase 2 Completed

43 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01813214 2019-02-26

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

Phase 2 Terminated

5 enrolled 7 charts

Dermatologic

Melanoma

NCT03340558 2018-10-09

ATELIER

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT01495988 2017-10-24

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Phase 2 Terminated

10 enrolled 10 charts

Dermatologic

Melanoma

Clinical Trials

TAPUR

CONCERTO

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

NACHO-COBI

ProTarget

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

ImmunoCobiVem

NEO-TIM

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Using Tumor Models to Determine Treatments

CRAFT: The NCT-PMO-1602 Phase II Trial

MEGALiT

FINPROVE

ECLIPSE

ROME

RadioCoBRIM

BEACON

REPOSIT

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

VECODUE

NEO-VC

COWBOY

CONVERCE

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

ATELIER

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma